Literature DB >> 23430552

Biochemical and Molecular Chitotriosidase Profiles in Patients with Gaucher Disease Type 1 in Minas Gerais, Brazil: New Mutation in CHIT1 Gene.

Talita E R Adelino1, Gustavo G Martins2, Aretta A A Gomes1, Adriana A Torres1, Daniel A S Silva1, Vinícius D O Xavier2, João Paulo O Guimarães2, Sérgio S S Araújo2, Rachel A F Fernandes2, Maria Christina L A Oliveira2, Ana Lúcia B Godard1, Eugênia R Valadares3,4,5.   

Abstract

Chitotriosidase (ChT) is a human chitinase secreted by activated macrophages and its activity is used in therapeutic monitoring of Gaucher disease (GD), the most common lysosomal storage disease. About 6% of the population is homozygous for a duplication of 24 bp in exon 11 of the CHIT1 gene (dup24), which is the main polymorphism that results in the absence of ChT. As ChT enzyme activity can be used as a biomarker in GD, it is important to know the CHIT1 genotype of each patient. In this study, ChT activity and CHIT1 genotype were evaluated in 33 GD type 1 patients under treatment in the state of Minas Gerais, Brazil, and compared to healthy controls. As expected, the enzyme activity was found to be higher in GD type 1 patients than in healthy subjects. Four patients had no ChT activity. Their genotype revealed three patients (9%) homozygous for dup24 allele and one patient with two polymorphisms in exon 11: G354R and a 4 bp deletion at the exon-intron 11 boundary (g.16993_16996delGAGT), the later described for the first time in literature. Two other patients with lower ChT activity presented a polymorphism in exon 4 (c.304G>A, p.G102S), without dup24 allele. In conclusion, this study demonstrated that ChT activity can be used for therapeutic monitoring in 82% of GD patients of the state of Minas Gerais, Brazil.

Entities:  

Year:  2012        PMID: 23430552      PMCID: PMC3565681          DOI: 10.1007/8904_2012_184

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  40 in total

1.  Plasma chitotriosidase activity in patients with beta-thalassemia.

Authors:  R Barone; F Di Gregorio; M A Romeo; G Schilirò; L Pavone
Journal:  Blood Cells Mol Dis       Date:  1999-02       Impact factor: 3.039

2.  Serial chitotriosidase activity estimations in neonatal systemic candidiasis.

Authors:  J Labadaridis; E Dimitriou; C Costalos; J Aerts; S van Weely; W E Donker-Koopman; H Michelakakis
Journal:  Acta Paediatr       Date:  1998-05       Impact factor: 2.299

3.  Beta-glucosidase activity in fibroblasts from homozygotes and heterozygotes for Gaucher's disease.

Authors:  E Beutler; W Kuhl; F Trinidad; R Teplitz; H Nadler
Journal:  Am J Hum Genet       Date:  1971-01       Impact factor: 11.025

Review 4.  A practical approach to diagnosis and management of Gaucher's disease.

Authors:  P K Mistry; A Abrahamov
Journal:  Baillieres Clin Haematol       Date:  1997-12

5.  Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages.

Authors:  R G Boot; T A van Achterberg; B E van Aken; G H Renkema; M J Jacobs; J M Aerts; C J de Vries
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

Review 6.  Ceramide signalling and the immune response.

Authors:  L R Ballou; S J Laulederkind; E F Rosloniec; R Raghow
Journal:  Biochim Biophys Acta       Date:  1996-06-11

7.  The diagnosis of the adult type of Gaucher's disease and its carrier state by demonstration of deficiency of beta-glucosidase activity in peripheral blood leukocytes.

Authors:  E Beutler; W Kuhl
Journal:  J Lab Clin Med       Date:  1970-11

8.  The human chitotriosidase gene. Nature of inherited enzyme deficiency.

Authors:  R G Boot; G H Renkema; M Verhoek; A Strijland; J Bliek; T M de Meulemeester; M M Mannens; J M Aerts
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

9.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Authors:  C E Hollak; S van Weely; M H van Oers; J M Aerts
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

10.  THE METABOLISM OF GLUCOCEREBROSIDES. I. PURIFICATION AND PROPERTIES OF A GLUCOCEREBROSIDE-CLEAVING ENZYME FROM SPLEEN TISSUE.

Authors:  R O BRADY; J KANFER; D SHAPIRO
Journal:  J Biol Chem       Date:  1965-01       Impact factor: 5.157

View more
  4 in total

1.  Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.

Authors:  Leelamma M Panicker; Diana Miller; Ola Awad; Vivek Bose; Yu Lun; Tea Soon Park; Elias T Zambidis; Judi A Sgambato; Ricardo A Feldman
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

2.  High prevalence of chitotriosidase deficiency in Peruvian Amerindians exposed to chitin-bearing food and enteroparasites.

Authors:  N Manno; S Sherratt; F Boaretto; F Mejìa Coico; C Espinoza Camus; C Jara Campos; S Musumeci; A Battisti; R J Quinnell; J Mostacero León; G Vazza; M L Mostacciuolo; M G Paoletti; F H Falcone
Journal:  Carbohydr Polym       Date:  2014-07-16       Impact factor: 9.381

3.  Chitotriosidase Activity and Gene Polymorphism in Iranian Patients with Gaucher Disease and Sibling Carriers.

Authors:  Hadi Mozafari; Mohammad Taghikhani; Shohreh Khatami; Mohammad Reza Alaei; Asad Vaisi-Raygani; Zohreh Rahimi
Journal:  Iran J Child Neurol       Date:  2016

4.  Early detection of lysosomal diseases by screening of cases of idiopathic splenomegaly and/or thrombocytopenia with a next-generation sequencing gene panel.

Authors:  Gloria Muñoz; David García-Seisdedos; Crina Ciubotariu; Miguel Piris-Villaespesa; Marta Gandía; Fernando Martín-Moro; Luis G Gutiérrez-Solana; Marta Morado; Javier López-Jiménez; Antonio Sánchez-Herranz; Jesús Villarrubia; Francisco J Del Castillo
Journal:  JIMD Rep       Date:  2019-12-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.